Volume 95 Issue 40 | p. 21 | Concentrates
Issue Date: October 9, 2017

CRISPR-focused KSQ launches

Department: Business
Keywords: start-ups, CRISPR, KSQ

KSQ Therapeutics has emerged from stealth mode with $76 million in funding from Polaris Partners to use the powerful gene-editing tool CRISPR to crack open a swath of new drug targets. Building on the work of its academic cofounders—David Sabatini and Tim Wang from MIT; William Hahn from Broad Institute; and Jonathan Weissman from the University of California, San Francisco—KSQ has developed a high-throughput method of using CRISPR to probe gene function. The biotech firm, which already has 40 employees, will initially focus on oncology and immunology drugs.

 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment